Net Income: $238 million for the first quarter of 2025. Adjusted EBITDA: $544 million for the first quarter of 2025. Phosphate Realized Prices: $623 per tonne, exceeding guidance ranges. Potash Realized Prices: $223 per tonne, exceeding guidance ranges. Phosphate Production: 1.4 million tonnes in the first quarter of 2025. Phosphate Cash Conversion Cost: $134 per tonne, with a target to reduce to $95-$100 per tonne by year-end. Potash Production Cash Cost: $78 per tonne, with a target to reduce to $64-$69 per tonne. Mosaic Fertilizantes Adjusted EBITDA: $122 million in the first quarter, with expectations to exceed $150 million in the second quarter. Free Cash Flow Generation: Constrained by typical working capital seasonality in the first quarter. Capital Expenditure (CapEx): Expected to be $1.2 billion to $1.3 billion for the year. SG&A Cost Savings: Achieved $90 million of the $150 million annual cost savings target. Mosaic Biosciences Revenue: More than doubled over the prior year, on track to double for the full year. Warning! GuruFocus has detected 8 Warning Sign with MOS. Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Fertilizer fundamentals are competitive with rising prices, and strong demand is observed in key growing regions globally. Mosaic Co is making progress in normalizing phosphate production and operating costs, aiming for stronger results in 2025 and beyond. The company's market access, particularly in Brazil, is enabling growth and benefiting from strong markets. Mosaic Biosciences is experiencing rapid growth, with revenue more than doubling over the prior year. The company is actively shedding noncore assets and reallocating capital to enhance shareholder returns. Negative Points Global trade conflicts and geopolitical forces are creating uncertainties, particularly affecting the US agriculture sector. Phosphate production faced substantial downtime due to planned turnarounds and reliability improvements, impacting costs. Potash production costs increased due to weather-related curtailments and maintenance work, affecting profitability. Free cash flow generation was constrained by typical working capital seasonality in the first quarter. The company faces potential demand headwinds in the second half of the year due to challenging fertilizer affordability. Q & A Highlights Q: How do you assess the progress at Bartow, New Wales, and Riverview in Louisiana, and what are the expectations for the second half of the year? A: Bruce Bodine, President and CEO, stated that the company is in a similar position as before, with some challenges during the turnaround season at New Wales and Bartow. Despite some unexpected maintenance issues, the reliability enhancement projects are paying off, and they are optimistic about the performance in the second half of the year. Story Continues Q: Are your ammonia costs rising due to tariffs, and how are you managing them? A: Bruce Bodine explained that their ammonia purchases have not incurred any tariff impacts so far. Most of their supply comes from the U.S., and they have strategic supply contracts that are tariff-free. They are also producing ammonia in Louisiana, minimizing exposure to market forces. Q: Can you provide insights into DAP price realizations and maintenance costs in phosphates? A: Jenny Wang, EVP - Commercial, noted that April DAP prices were higher than anticipated, and the market is expected to remain strong. Bruce Bodine added that maintenance costs were impacted by fixed cost absorption and extraordinary maintenance, but they anticipate costs to normalize as production improves. Q: How do you view the potash market given the recent Belarusian exports and supply dynamics? A: Jenny Wang acknowledged that Belarusian exports have not decreased as expected, but there have been production cuts in China and Chile. The low inventory situation in China is expected to support future contract negotiations, and the overall potash market remains tight. Q: What is the outlook for Mosaic Biosciences, and is there a plan to spin it off? A: Jenny Wang highlighted that Mosaic Biosciences is targeting $70 million in revenue this year, with profitability expected in Q4. The business is growing through both proprietary and licensed products, with gross margins of 60% and 30-40%, respectively. Bruce Bodine mentioned that they see potential for further growth and are considering valuation benefits as the business expands. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
The Mosaic Co (MOS) Q1 2025 Earnings Call Highlights: Strong Performance Amidst Market Challenges
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...